Senseera
Tel Aviv, Israel· Est.
AI‑powered cfChIP‑seq liquid biopsy delivering cell‑state biomarkers from a simple blood draw.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $7.1M
AI Company Overview
AI‑powered cfChIP‑seq liquid biopsy delivering cell‑state biomarkers from a simple blood draw.
HepatologyOncologyTransplantImmunologyMetabolic Disease
Technology Platform
AI‑driven cfChIP‑seq liquid biopsy that captures and sequences active cell‑free chromatin from plasma to generate high‑resolution cell‑state gene‑expression biomarkers.
Opportunities
Expansion of cfChIP‑seq diagnostics into additional organ‑specific diseases and partnership with pharma for companion diagnostics could drive rapid revenue growth.
Risk Factors
Regulatory approval, reimbursement uncertainty, and competition from established DNA‑based liquid biopsy firms could limit market adoption.
Competitive Landscape
Key competitors include Guardant Health, GRAIL and Illumina’s liquid‑biopsy offerings; Senseera differentiates through epigenetic, cell‑state biomarkers rather than mutation detection.